Using the manufacturing process described here, the authors obtained an overall 45-fold increase over a conventional batch culture of product concentration from 15 to 700 mg/L compared with a batch culture in serum-containing medium.
This article describes the development and scale-up of a process used to manufacture a murine immunoglobulin (IgM) obtained from the suspension culture of hybridomas in serum-free medium. The IgM binds to the otp receptor on the surface of T cells. It is intended for use in clinical settings where T-cell immunosuppression is desired, such as in treating acute cellular rejection in solid organ transplantation patients and for preventing …
No comments:
Post a Comment